MULTIPLE MYELOMA – How translational research transformed and guides clinical practice and vice versa – For both scientists and clinicians
February 25-27, 2027 – Vienna, Austria
Chairs: Hermann Einsele, Martin Kaiser, Omar Nadeem, Sonja Zweegman

Thursday, February 25, 2027

08:00-08:10	**Welcome**	Conference chairpersons

SESSION I – The non-smouldering developments in smouldering myeloma
Chairs: Shaji Kumar (Rochester), Omar Nadeem (Boston)

08:10-08:17	Flash talk: Importance of biology	Rosa Toenges (Boston)
08:17-08:20	*Discussion*	
08:20-08:27	Case presentation: Clinical phase I/II SMM study	Tarek Mouhieddine (Boston)
08:27-08:30	*Discussion*	
08:30-08:45	Epidemiology	Sigurdur Kristinsson (Reykjavík)
08:45-08:50	*Discussion*	
08:50-09:05	Genomic profiling and the impact on therapeutic choices	Brian Walker (Miami)
09:05-09:10	*Discussion*	
09:10-09:25	Immunologic profiling and the impact on therapeutic choices	Irene Ghobrial (Boston)
09:25-09:30	*Discussion*	
09:30-09:45	Current and future clinical trials in SMM	Omar Nadeem (Boston)
09:45-09:50	*Discussion*	
09:50-10:20	*Panel discussion*	
10:20-10:50	***Coffee break and Poster viewing***	

10:50-11:30 **DEBATE 1 – To treat or not to treat SMM**
Chairs: Maria Krauth (Vienna), Sonja Zweegman (Amsterdam)

Audience votes

10:50-11:05	To treat	Shaji Kumar (Rochester)
11:05-11:20	Not to treat	Heinz Ludwig (Vienna)
11:20-11:30	*Discussion*	

Audience votes again

11:30-12:10 KEYNOTE LECTURE 1
Chairs: Nizar Bahlis (Calgary), Salomon Manier (Lille)

11:30-12:00	Resistance mechanisms	Nizar Bahlis (Calgary)
12:00-12:10	*Discussion*	

12:10-14:05 Lunch

***12:55-13:55* Possible slot for a satellite symposium**

14:05-15:35 TUMOUR BOARD 1 – The reality of CAR-T and BsAb therapy - sequencing matters!
Chairs: Hermann Einsele (Würzburg), Sonja Zweegman (Amsterdam)

14:05-14:15	A patient case of CAR-T cell therapy within 6 months of prior BsAb therapy	Surbhi Sidana (Stanford)
14:15-14:35	*Expert discussion – Maria Krauth (Vienna), Leo Rasche (Würzburg), Surbhi Sidana (Stanford)* *Interactive discussion with the audience*	
14:35-14:45	A patient case with RRMM heavily pretreated and being treated with BsAb therapy - following bridging with chemotherapy	Shonali Midha (Boston)
14:45-15:05	*Expert discussion – Tarek Mouhieddine (Boston), Shonali Midha (Boston)* *Interactive discussion with the audience*	
15:05-15:15	Case Presentation: Bispecific antibody after prior CAR T cell therapy	Salomon Manier (Lille)
15:15-15:35	*Expert discussion – Salomon Manier (Lille), Surbhi Sidana (Stanford)* *Interactive discussion with the audience*	

15:35-16:05 Coffee break and Poster viewing

SESSION II – What to do first in first-line therapy - controversies
Chairs: Francesca Gay (Turin), Charlotte Pawlyn (London)

16:05-16:12	Case presentation: Young newly diagnosed multiple myeloma patient with high-risk disease	Lina Rüsing (Vienna)
16:12-16:15	*Discussion*	
16:15-16:30	Derisking high-risk patients in first line	Martin Kaiser (London)
16:30-16:35	*Discussion*	
16:35-16:42	Case presentation: fit NTE patient: either quadruple or not?	Febe Smits (Amsterdam)
16:42-16:45	*Discussion*	
16:45-17:00	Quads for everybody	Salomon Manier (Lille)
17:00-17:05	*Discussion*	
17:05-17:12	Case presentation: Frail patient	Maria Krauth (Vienna)
17:12-17:15	*Discussion*	
17:15-17:30	How to treat the frail patient with multiple myeloma	Sonja Zweegman (Amsterdam)
17:30-17:35	*Discussion*	
17:35-17:40	Brief oral communication	*Speaker*

17:40-17:43 *Discussion*

17:43-18:00 Panel discussion

18:00-19:30 ***Poster Walks and Welcome Get Together stand-up buffet dinner***
Poster leaders: TBA

Friday, February 26, 2027

08:00-09:00 **3 Simultaneous Breakfast Meet the Expert Sessions**

1. CAR-T cells — Michael Hudecek (Würzburg)
2. Bispecifics — Marc Raab (Heidelberg)
3. MRD — Claudio Cerchione (Bologna)

09:10-09:50 **KEYNOTE LECTURE 2**
Chairs: Hermann Einsele (Würzburg), Nikhil Munshi (Boston)*

09:10-09:40 T-cell exhaustion — Andrea Schietinger (New York)
09:40-09:50 *Discussion*

09:50-10:30 **DEBATE 2 – CAR-T cells or Bispecifics?**
Chairs: Martin Kortüm (Würzburg), Maria Krauth (Vienna)

Audience votes

09:50-10:05 CAR-T cells — Thomas G. Martin (San Francisco)

10:05-10:20 Bispecifics — Marc Raab (Heidelberg)

10:20-10:30 *Discussion*

Audience votes again

10:30-11:00 Coffee Break and Poster viewing

SESSION III – Moving earlier to T-cell therapies in early relapse
Chairs: Thomas G. Martin (San Francisco), Paula Rodriguez Otero (Pamplona)

11:00-11:07 Case presentation: First relapse in a fit patient — Francesca Gay (Turin)
What to choose between all regimens being investigated after 1-3 prior lines of therapy
11:07-11:10 *Discussion*

11:10-11:17 Case presentation: First relapse in a less fit patient - balancing benefit and risk — Felix Czernilofsky (Heidelberg)
11:17-11:20 *Discussion*

11:20-11:35 BCMA - yes, but driving the CAR or switching gears — Charlotte Pawlyn (London)
11:35-11:40 *Discussion*

11:40-11:55 Away from side effects - how to prevent, reduce and overcome! — Paula Rodriguez Otero (Pamplona)
11:55-12:00 *Discussion*

12:00-12:15	DreaMMs come alive - the role of ADC in earlier lines of therapy	Evangelos Terpos (Athens)
12:15-12:20	*Discussion*	
12:20-12:35	Novel CAR constructs and concepts	Michael Hudecek (Würzburg)
12:35-12:40	*Discussion*	
12:40-13:05	*Panel discussion*	
13:05-15:00	***Lunch***	
13:50-14:50	**Possible slot for a satellite symposium**	

SESSION IV – How to treat in later lines when T-cell have become exhausted treating
Chairs: Pieter Sonneveld (Rotterdam), Evangelos Terpos (Athens)

15:00-15:07	Flash talk: Biology of T-cell exhaustion	Sofie-Katrin Kadel (Würzburg)
15:07-15:10	*Discussion*	
15:10-15:17	Flash talk: Novel drug testing	Torsten Steinbrunn (Würzburg)
15:17-15:20	*Discussion*	
15:20-15:35	Role of spatial transcriptomics in unraveling and finding novel therapies	Angela Riedel (Würzburg)
15:35-15:40	*Discussion*	
15:40-15:45	Brief oral communication	*Speaker*
15:45-15:48	*Discussion*	
15:48-16:10	*Panel discussion*	
16:10-16:40	***Coffee Break and Poster viewing***	

16:40-17:50 TUMOUR BOARD 2 – Gain greater insight through a deep and broad perspective: the role of deep sequencing and spatial transcriptomics
Chairs: Martin Kortüm (Würzburg), Leo Rasche (Würzburg)

16:40-16:55	Tumor intrinsic resistance mechanisms	Nizar Bahlis (Calgary)
16:55-17:15	*Expert discussion – Nizar Bahlis (Calgary), Hermann Einsele (Würzburg), Marc Raab (Heidelberg), Leo Rasche (Würzburg)* *Interactive discussion with the audience*	
17:15-17:30	Microenvironment	Madhav Dhodapkar (Seattle)
17:30-17:50	*Expert discussion – Nizar Bahlis (Calgary), Madhav Dhodapkar (Seattle), Leo Rasche (Würzburg), Kenneth C. Anderson (Boston)** *Interactive discussion with the audience*	

17:50-18:30 DEBATE 3 – Will we still do transplants in 2030
Chairs: Omar Nadeem (Boston), Sonja Zweegman (Amsterdam)

Audience votes

17:50-18:05	Transplant first line	Saad Usmani (New York)
18:05-18:20	No transplant first line	Leo Rasche (Würzburg)

18:20-18:30 *Discussion*

Audience votes again

Saturday, February 27, 2027

08:30-09:10 KEYNOTE LECTURE 3
Chairs: Hermann Einsele (Würzburg), Omar Nadeem (Boston)

08:30-09:00 Myeloma therapy 2030 — Kenneth C. Anderson (Boston)
09:00-09:10 *Discussion*

09:10-10:40 TUMOUR BOARD 3 – Treatment endpoints in multiple myeloma
Chairs: Martin Kortüm (Würzburg), Nikhil Munshi (Boston)

09:10-09:20 Case presentation: MRD — Nikhil Munshi (Boston)
09:20-09:40 *Expert discussion - Hermann Einsele (Würzburg), Nikhil Munshi (Boston), Sonja Zweegman (Amsterdam)*
Interactive discussion with the audience

09:40-09:50 Case presentation: Imaging — Elena Zamagni (Bologna)
09:50-10:10 *Expert discussion – Paula Rodriguez Otero (Pamplona), Saad Usmani (New York), Elena Zamagni (Bologna)*
Interactive discussion with the audience

10:10-10:20 Case report 1
Should therapy be changed if patient remains MRD positive? — Michele Puppi (Bologna)
10:20-10:30 Case report 2
Should therapy be discontinued if patient achieves MRD negativity? — Klaus Podar (Vienna)
10:30-10:40 *Expert discussion – Nikhil Munshi (Boston), Klaus Podar (Vienna), Michele Puppi (Bologna), Elena Zamagni (Bologna)*
Interactive discussion with the audience

10:40-11:10 Coffee break and Poster viewing

SESSION VI – Hot topics
Chairs: Hermann Einsele (Würzburg), Sonja Zweegman (Amsterdam)

11:10-11:25 EMD — Hermann Einsele (Würzburg)
11:25-11:30 *Discussion*

11:30-11:45 Waldenstöm — Steven Treon (Boston)
11:45-11:50 *Discussion*

11:50-12:05 Maintenance therapy duration — Pieter Sonneveld (Rotterdam)
12:05-12:10 *Discussion*

12:10-12:25 Amyloidosis — Efstathios Kastritis (Athens)
12:25-12:30 *Discussion*

12:30-12:35 Brief oral communication — *Speaker*

12:35-12:40 Discussion

12:40-13:05 Panel discussion

13:05-13:10 Closing remarks

MEETING CLOSURE

**Pending confirmation*